What is Pancreatic Cancer?

Pancreatic cancer is very aggressive and often found late because early symptoms remain unclear. The pancreatic ductal adenocarcinoma (PDAC) is the most common type of cancer, accounting for about 90% of cases. Other less common types include neuroendocrine tumors (NETs), which generally have a better prognosis. Rare forms like acinar cell carcinoma also exist.

This form of cancer is fatal because it has the potential to metastasize to nearby structures such as blood vessels, bile ducts, or the duodenum. In addition, it has the potential to metastasize to the liver, lungs, or abdomen. Despite the advancements in surgery, chemotherapy, and the newly introduced targeted therapies, pancreatic cancer remains the third leading cause of cancer deaths. There has been a minimal improvement in survival over the years.

In the United States, about 67,530 new cases and 52,740 deaths are expected in 2026, making pancreatic cancer the 3rd major cause of cancer death after lung and colorectal cancers. The incidence rate is about 13.8 per 100,000 people, with a death rate of 11.3 per 100,000. The overall five-year survival rate is about 13%, and it hasn't really increased much compared to other types of cancer, which have a 70% survival rate. The survival rate ranges from 44% for localized cancer to 3% for distant cancer.

Worldwide, pancreatic cancer cases are increasing, mainly because of aging populations, rising obesity, diabetes, and lifestyle changes. In 2022, the number of new cases worldwide exceeded 510,000. This is expected to increase over time, especially by 2050. In Asia, the expected number of cases among the aging population is 487,000. The death rates are also expected to follow the new cases since it is difficult to detect the disease at an early stage.

The incidence of cases of pancreatic cancer in our country (India) is much lower than in Western countries, but is increasing, particularly in cities where lifestyle changes are taking place. According to new statistical data, the incidence rate of pancreatic cancer is about 13,661 new cases per year, and the rate is increasing to 0.96 per 100,000 people. The incidence rate is also expected to increase from 2025 to 2030 due to various reasons, such as diabetes, smoking, and dietary habits. In states such as Uttar Pradesh, in cities such as Lucknow and Kanpur, patients are generally diagnosed at a late stage due to a lack of awareness and access to specialized medical treatment. The lifetime risk is low, and a greater incidence of digestive tract cancers is seen in urban areas.

At Tender Palm Super Specialty Hospital in Lucknow, we are committed to providing our patients with pancreatic cancer the best possible treatment. Our team firmly believes that early detection, proper staging, and effective planning are key to the successful treatment of patients with pancreatic cancer.

What are the Symptoms of Pancreatic Cancer?

The symptoms associated with pancreatic cancer generally develop late once the growth has progressed beyond an early stage. The symptoms may mimic more typical conditions such as indigestion, gallbladder problems, or diabetes.

Common symptoms include:

• Jaundice: It causes yellowing of the skin and eyes, dark urine, and pale stools, which often happens when tumors in the head of the pancreas block the bile duct. abdominal or back pain (dull, persistent, worse after eating or lying down; may radiate to the mid-back)
• Unexplained weight loss and loss of appetite
• New or worsening diabetes, especially if over 50 years old without risk factors
• Nausea, vomiting, or indigestion
• Fatigue or weakness
• Feeling bloated or full too quickly
• Changes in stool, such as greasy or floating stools that are hard and most difficult to flush down the toilet, are caused by poor fat digestion.
• Itching from jaundice

Less common but serious signs include blood clots (deep vein thrombosis), depression, which can be an early sign of paraneoplastic syndromes, and ascites, a buildup of fluid in the abdomen.

What are the Causes and Risk Factors for Pancreatic Cancer?

The causes of cancer involve many factors, including genetic mutations that drive cell growth. The risk factors for cancer are:

Modifiable risk factors:

• Smoking, which doubles the risk and is responsible for 25% of cases
• Obesity, with a 20% increased risk if the BMI is >30
• Excessive alcohol use is associated with chronic pancreatitis.
• Poor dietary routine/habits, with a high intake of red/processed meat and a low intake of fruits/vegetables
• Sedentary lifestyle

Non-modifiable and medical risk factors:

• Age: the majority of cases are >60-65 years of age, with cases under 40 years of age being rare
• Type 2 diabetes (long-standing increases risk; new-onset in older adults can be a warning sign)
• Chronic pancreatitis (inflammation of the pancreas)
• Family history (first-degree relatives with pancreatic cancer)
• Inherited genetic syndromes/mutations (BRCA1/2, Lynch syndrome, Peutz-Jeghers, familial atypical multiple mole melanoma, hereditary pancreatitis, PALB2)
• Race/ethnicity (higher). No single cause explains most cases, but combinations like smoking, diabetes, and obesity greatly increase the risk. In India, the rise in diabetes and metabolic syndrome is driving these trends. They contribute to increasing trends.

How is Pancreatic Cancer Diagnosed ?

Identifying patients with pancreatic cancer can be difficult because of the nonspecific nature of the symptoms. Screening is not routinely performed on average-risk individuals because pancreatic cancer is uncommon, and no reliable and cheap tests are available yet.

Diagnosis requires:

• History & Physical examination - Checking for jaundice, tenderness in the abdomen, unexplained weight loss, or masses.
• Blood test
• Liver function test (increased bilirubin and alkaline phosphatase in case of jaundice)
• Tumor markers: CA 19-9 (commonly increased but non-specific; helpful in follow-up)
• Glucose/HbA1c for new diabetes
• Complete blood count and other routine tests. A pancreatic protocol CT scan with triple-phase contrast is the first test used to detect and stage the cancer.
• MRI/MRCP (magnetic resonance cholangiopancreatography) for detailed duct visualization
• Endoscopic ultrasound (EUS) with fine-needle aspiration/biopsy — highly accurate for tissue diagnosis
• PET-CT for assessing metastases or a biopsy using endoscopic ultrasound (EUS) with fine-needle aspiration or core biopsy confirms the cancer and is essential before starting treatment.

Additional Tests

• ERCP (endoscopic retrograde cholangiopancreatography) for biliary stenting in jaundice, genetic testing for BRCA, and other tests to guide targeted cancer therapy
• AJCC/TNM System: the cancer stages are:
• Stage 0/I: Confined to pancreas (resectable)
• Stage II: Locally extended but potentially resectable
• Stage III: Locally advanced/unresectable (vascular involvement
• Stage IV: Distant metastases

Approximately 80% of problems are diagnosed at stage III or IV. Early imaging can miss some spread, and up to 80% of patients are found to have more advanced disease during surgery.

What are the Management and Treatment Options for Pancreatic Cancer?

It involves a team approach and depends on the cancer stage, patient health, and molecular features. The goals are to cure when possible (rare; only if the tumor can be removed), extend survival, and maintain quality of life.

Surgery

(only ~15-20% of patients are candidates):

• Whipple procedure (pancreaticoduodenectomy) for head tumors
• Distal pancreatectomy or total pancreatectomy for body/tail
• In borderline situations, vascular resection or repair

Patients recover more quickly with minimally invasive procedures, such as robotic or laparoscopic surgery.

To reduce borderline tumors for better excision, neoadjuvant therapy (chemotherapy plus radiation) is frequently utilized.

Chemotherapy:

• First-line treatment for advanced disease: FOLFIRINOX (more intensive and for fit patients) or Gemcitabine with nab-Nalirifox, a new combination of FDA-approved drugs, has demonstrated improved outcomes.
• Adjuvant treatment after surgery: Modified FOLFIRINOX or Gemcitabine

Targeted Therapy:

• PARP Inhibitors (Olaparib) in maintenance treatment in BRCA-mutated cases
• KRAS Inhibitors (emerging in common G12D/V mutations in KRAS)
• Other: In cases of less common mutations

Immunotherapy:

Immunotherapy has limited success in most cases because these tumors have low mutation levels and an environment that suppresses the immune response.

• Pembrolizumab for MSI-high/dMMR cases (~1–2%)
• Trials combining checkpoint inhibitors with chemo or vaccines

Radiation:

• Stereotactic body radiotherapy (SBRT) for locally advanced
• Radiation is also the most effective way to treat the problem, and can be used to relieve pain or blockages.

Supportive care:

• Biliary stenting for Managing pain, nutrition, and other supportive care needs, palliative interventions
• Trials of vaccines, new combinations of therapies (e.g., TT Fields + chemo), and biomarkers for early detection are under investigation.

What is the Prognosis for Pancreatic Cancer?

The 5-year survival rate is only 13% overall, according to the latest U.S. statistics available up to 2026. By the stage of diagnosis:

• Localized/resectable: 44%
• Regional: 17%
• Distant/metastatic: 3%

The median survival rate for chemotherapy in the treatment of metastatic cancer is 8 to 12 months. The median survival rate for those with a BRCA mutation and undergoing treatment with a PARP inhibitor is 24 months or longer.

Patients who have a BRCA mutation and are using a PARP inhibitor can survive longer than 24 months. Success is also related to the removal of cancer, the patient, and targeted treatment. In India, cancer patients do not do as well because of the late-stage cancer when treatment is sought. However, some centers are reporting good results from a combination of treatments. Cancer comes back after treatment, and follow-up becomes crucial.

New approaches, such as pre-surgery treatments, genetic testing, and emerging therapies, offer hope of gradual improvements.

Why choose Tender Palm Super-Speciality Hospital for Pancreatic Cancer Treatment in Lucknow, India?

Tender Palm Super-Speciality Hospital offers advanced Pancreatic Cancer treatment in Lucknow, India, at an affordable cost. We have a team of experienced pancreatic surgeons and oncology specialists who provide accurate diagnosis and both non-surgical and surgical treatment options including Whipple procedure, chemotherapy, and targeted therapy. Our Pancreatic Surgery and Oncology team has decades of experience in successfully treating Pancreatic Cancer in Lucknow, India.

To seek an Expert consultation for Pancreatic Cancer Treatment in Lucknow, India:

Call us at +91-9076972161
Email at care@tenderpalm.com

Request a Call Back